"Immunogenicity, tolerance and reactogenicity of Quimi-Hib and alum phospate adjuvanted Quimi-Hib vaccines in healthy infants according to 6 - 10 - 14 weeks primary vaccination series. A multicenter, controlled, randomized, doubled blind clinical trial."
Phase of Trial: Phase II
Latest Information Update: 07 Sep 2016
At a glance
- Drugs Hib vaccine conjugate (Primary) ; Aluminium phosphate
- Indications Haemophilus infections
- Focus Therapeutic Use
- 28 Sep 2012 New trial record